Document is current
Any future updates will be listed below
-
Authors
Ventura, Pedro M O
Gakovic, Milica
Fischer, Berenice A
Spinelli, Laura https://orcid.org/0000-0002-5801-6297
Rota, Giorgia
Pathak, Shalini https://orcid.org/0000-0001-9871-2214
Khameneh, Hanif J https://orcid.org/0000-0002-1737-0388
Zenobi, Alessandro https://orcid.org/0000-0003-2837-7638
Thomson, Sarah
Birchmeier, Walter
Cantrell, Doreen A
Guarda, Greta https://orcid.org/0000-0001-9243-6116
-
Funding
Funding for this research was provided by:
Fondazione San Salvatore, Lugano
Leonardo Foundation, Lugano
Novartis Foundation, Basel
Swiss Cancer Research Foundation (KFS 5141‐08‐2020)
Swiss National Science Foundation (310030_185185)
Swiss National Science Foundation (310030_197771)
Wellcome Trust Principal Research Fellowship (205023/Z/16/Z)
- License Information
-
More Information
Article History
Received: 16 May 2022
Revised: 5 September 2022
Accepted: 8 September 2022
First Online: 4 October 2022
Disclosure and competing interests statement
: Unrelated projects in GG laboratory are supported by OM‐Pharma, Meyrin, and IFM Therapeutics, Boston. DAC has collaborations with GlaxoSmithKline and Division of Signal Transduction Therapy (DSTT), involving collaborations with Merck, Boehringer Ingleheim, and GSK. The other authors declare no competing interests.
